The spokesperson of Aurobindo Pharma said there are no repeat observations or anything related to data integrity and that they are in the process of submitting a response to the USFDA.from Moneycontrol Business News https://ift.tt/2W8afJw
Friday, August 20, 2021
Aurobindo Pharma Unit-1 gets 7 observations; company says responding to USFDA
The spokesperson of Aurobindo Pharma said there are no repeat observations or anything related to data integrity and that they are in the process of submitting a response to the USFDA.from Moneycontrol Business News https://ift.tt/2W8afJw
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment